NanoViricides, Inc. (NASDAQ:NNVC)

PRESS RELEASE

published on 10/20/2025 at 14:45, 5 months 6 days ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
NanoViricides, Inc. announces NV-387, a drug showing strong activity against Measles virus in an animal model, available for emergency use. Drug has completed Phase I clinical trial

NanoViricides NV-387 Emergency Use Measles Virus Phase I
BRIEF

published on 10/15/2025 at 14:50, 5 months 11 days ago

NanoViricides poursuit une stratégie clinique à double voie pour le NV-387

Antiviral À Large Spectre Essais De Phase II Développement NV-387 Essai MPox Virus Respiratoires
BRIEF

published on 10/15/2025 at 14:50, 5 months 11 days ago

NanoViricides Pursues Dual-Track Clinical Strategy for NV-387

Respiratory Viruses Broad-spectrum Antiviral Phase II Trials NV-387 Development MPox Trial
PRESS RELEASE

published on 10/15/2025 at 14:45, 5 months 11 days ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
NanoViricides, Inc. reveals dual-track clinical development strategy for NV-387 targeting respiratory viral infections including Influenzas, Coronaviruses, RSV. Analyst report details trials and future prospects

Respiratory Viral Infections NV-387 NanoViricides Inc. Analyst Report Clinical Development Strategy
BRIEF

published on 09/30/2025 at 14:50, 5 months 26 days ago

Progrès du NV-387 de NanoViricides dans les essais cliniques

NanoViricides NV-387 Essais Cliniques Thérapie Antivirale Défis De Financement
BRIEF

published on 09/30/2025 at 14:50, 5 months 26 days ago

NanoViricides' NV-387 Advances in Clinical Trials

NanoViricides NV-387 Clinical Trials Antiviral Therapy Funding Challenges
PRESS RELEASE

published on 09/30/2025 at 14:45, 5 months 26 days ago

NanoViricides, Inc. Has Filed its Annual Report
NanoViricides reports progress on antiviral NV-387 in Phase II clinical trials with potential to revolutionize treatment for respiratory viral infections. Annual report highlights achievements and funding status

NanoViricides NV-387 Clinical Trials Respiratory Infections Antiviral
BRIEF

published on 09/11/2025 at 14:35, 6 months 15 days ago

NanoViricides to Present at LSX World Congress in Boston

NanoViricides NV-387 Clinical Trials Antiviral Drug LSX Congress
BRIEF

published on 09/11/2025 at 14:35, 6 months 15 days ago

NanoViricides sera présenté au congrès mondial LSX à Boston

NanoViricides NV-387 Essais Cliniques Médicament Antiviral Congrès LSX
PRESS RELEASE

published on 09/11/2025 at 14:30, 6 months 15 days ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
NanoViricides, Inc. announces participation in LSX World Congress 2025 to present revolutionary broad-spectrum antiviral drug NV-387 and potential impact on viral infections

NanoViricides NV-387 Antiviral Drug Viral Infections LSX World Congress

Published on 03/26/2026 at 14:05, 1 hour 13 minutes ago

SouthGobi Announces Profit Warning
Published on 03/26/2026 at 13:00, 2 hours 18 minutes ago

Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 2 hours 18 minutes ago

GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 12:59, 2 hours 19 minutes ago

Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance
Published on 03/26/2026 at 12:45, 2 hours 33 minutes ago

Quartz Mountain Reports Strong Warrant Exercise Participation and Provides Exploration Update at Maestro Project, Central British Columbia

View all ACCESSWIRE

Published on 03/26/2026 at 15:05, 13 minutes ago

JOY GROUP Announces 2025 Financial Results, Revenue Surpasses US$620M
Published on 03/26/2026 at 15:01, 16 minutes ago

EQS-Adhoc: CENIT AG decides to switch from the Regulated Market (Prime Standard) to the Scale Segment of the Frankfurt Stock Exchange
Published on 03/26/2026 at 15:00, 18 minutes ago

OLB’s financial performance remains at a consistently high level
Published on 03/26/2026 at 14:35, 43 minutes ago

Guidepoint Library Surpasses 100,000 Transcripts, Scaling Real-Time Access to Expert Knowledge
Published on 03/26/2026 at 14:30, 48 minutes ago

Delticom publishes Annual Report 2025: Revenues slightly higher than last year, dividend proposal of € 0.12 per share

View all EQS

Published on 03/26/2026 at 08:57, 6 hours 20 minutes ago

Communiqué Edenred
Published on 03/26/2026 at 08:57, 6 hours 20 minutes ago

Edenred statement
Published on 03/26/2026 at 07:30, 7 hours 48 minutes ago

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/26/2026 at 07:30, 7 hours 48 minutes ago

BIOPHYTIS ET LYNXKITE INVITÉS À LA CONFÉRENCE NVIDIA : L’IA AU SERVICE DE LA LONGÉVITÉ
Published on 03/25/2026 at 18:53, 20 hours 24 minutes ago

CIS - Transfert Contrat de Liquidité Portzamparc - 25.03.2026

View all LES ECHOS COMFI WIRE

News